Table 4.
Effect of Aspirin on Oxylipids
| Name | Precursor | Enzyme | Pre‐aspirin | Postaspirin | % Change | P value | Q value |
|---|---|---|---|---|---|---|---|
| TXB2 | AA | COX | 241.3±245.8 | 7±12.9 | −97 | 1.9×10−26 | 3.2×10−25 |
| 12‐HHTrE* | AA | COX | 1.8±1.8 | 0.2±0.1 | −87 | 2.3×10−26 | 3.2×10−25 |
| 11‐HETE | AA | COX | 13.7±11.9 | 1.8±1.2 | −85 | 3.3×10−26 | 3.2×10−25 |
| 15‐HETE | AA | 15‐LOX | 16.2±12.9 | 5.2±3.6 | −67 | 1.7×10−24 | 1.2×10−23 |
| 12‐HEPE | EPA | 12‐LOX | 26.2±34.5 | 11.1±17.4 | −60 | 3.3×10−13 | 8.2×10−13 |
| 12‐HETE* | AA | 12‐LOX | 1.3±1.4 | 0.7±1 | −53 | 8×10−13 | 1.2×10−12 |
| 15‐HETrE | DGLA | 15‐LOX | 3.2±1.5 | 1.8±0.9 | −45 | 9×10−22 | 5.8×10−21 |
| 15‐HEPE | EPA | 15‐LOX | 1.7±1.1 | 1±0.7 | −44 | 5×10−16 | 2.1×10−15 |
| 8‐HETE | AA | 15‐LOX | 5.5±3.6 | 3.4±2.6 | −43 | 1.4×10−12 | 3×10−12 |
| PGF2α | AA | COX | 5.9±3.4 | 3.9±2.3 | −31 | 7.4×10−20 | 3.7×10−19 |
| 9‐HOTrE | ALA | 5‐LOX | 1±0.5 | 0.7±0.4 | −31 | 9.2×10−10 | 1.5×10−9 |
| 9‐HODE | LA | 5‐LOX | 19.7±9.5 | 14±6.4 | −29 | 7.3×10−14 | 2.4×10−13 |
| 5‐HEPE | EPA | 5‐LOX | 4.4±3.3 | 3±2 | −28 | 2.5×10−13 | 6.7×10−13 |
| 5,6‐DiHETrE | AA | CYP | 3.9±1.8 | 2.8±1.3 | −27 | 3.6×10−14 | 1.3×10−13 |
| 13‐HODE | LA | 15‐LOX | 21.3±10 | 15.8±7.7 | −27 | 6.5×10−12 | 1.3×10−11 |
| 5‐HETE | AA | 5‐LOX | 13.6±6.2 | 10.4±5.3 | −26 | 2.5×10−13 | 6.7×10−13 |
| 12,13‐DiHOME | LA | CYP | 11.7±6 | 10.3±5.7 | −19 | 1.3×10−4 | 1.6×10−4 |
| 20‐HETE | AA | CYP | 7.2±2.8 | 5.9±2.2 | −19 | 1.9×10−8 | 2.8×10−8 |
| 11,12‐DiHETrE | AA | CYP | 3.5±1.2 | 2.9±0.9 | −16 | 9.2×10−10 | 1.5×10−9 |
| 9‐KODE | LA | 5‐LOX | 2.6±1.8 | 2.2±1.6 | −15 | 1.1×10−7 | 1.5×10−7 |
| 9,10‐DiHOME | LA | CYP | 6.3±4 | 5.5±3.9 | −15 | 1×10−4 | 1.3×10−8 |
| 8,9‐DiHETrE | AA | CYP | 2.3±0.7 | 2±0.6 | −14 | 1.8×10−9 | 2.8×10−8 |
| PGF1α | DGLA | COX | 2.6±0.5 | 2.2±0.4 | −11 | 1.5×10−11 | 2.8×10−11 |
| 9,10‐EpOME | LA | CYP | 3±2.1 | 2.4±2 | −11 | 1.3×10−6 | 1.7×10−6 |
| 12,13‐EpOME | LA | CYP | 5±3.3 | 4.6±3 | −11 | 8.5×10−3 | 9.4×10−3 |
| 14,15‐DiHETrE | AA | CYP | 4.8±1.2 | 4.3±1.1 | −9 | 7.8×10−8 | 1.1×10−7 |
| 9,12,13‐TriHOME | LA | 5/15‐LOX | 1.5±0.6 | 1.4±1 | −3 | 0.036 | 0.038 |
| 13,14‐dihydro‐PGF2α | AA | COX | 39.9±6.5 | 41.9±6.2 | 3 | 0.004 | 0.005 |
| 19,20‐DiHDPA | DHA | CYP | 7.3±3.2 | 7.1±3 | −2 | 0.56 | 0.56 |
| LTB4 | AA | 5‐LOX | 3.1±3.7 | 2.6±3 | 0 | 0.06 | 0.06 |
Data represent mean±SD of metabolite concentrations (nmol/L) in all subjects (n=156) pre‐ and postaspirin treatment and median % change. Absolute concentrations could not be determined for metabolites with an asterisk, so data represent mean±SD of metabolite levels divided by the mean metabolite level detected in this study. AA indicates arachidonic acid; ALA, α‐linolenic acid; COX, cyclooxygenase; CYP, cytochrome P450; DGLA, dihomo‐γ‐linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; LOX, lipoxygenase.